DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0190359 A1 Venkatraman Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0190359 A1 Venkatraman Et Al US 2015O190359A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0190359 A1 Venkatraman et al. (43) Pub. Date: Jul. 9, 2015 (54) STABLE LIPOSOMAL FORMULATIONS FOR Publication Classification OCULAR DRUG DELVERY (51) Int. Cl. (71) Applicants:Nanyang Technological University, A63L/216 (2006.01) Singapore (SG); Singapore Health A 6LX 9/27 (2006.01) Services Pte Ltd., Bowyer Block (SG) (52) U.S. Cl. CPC ............... A61 K3I/216 (2013.01); A61K 9/127 (72) Inventors: Subramanian Venkatraman, Singapore (2013.01) (SG); Jayaganesh V. Natarajan, Singapore (SG); Tina Howden, (57) ABSTRACT Singapore (SG); Freddy Boey, Singapore (SG) A stable liposomal formulation for ocular delivery. The for mulation contains a liposome that includes at least one lipid (21) Appl. No.: 14/149,159 bilayer containing a phosphatidylcholine, and a prostaglan din F, encapsulated in the liposome. Also provided is a (22) Filed: Jan. 7, 2014 method for treating an ocular disorder with the formulation. Patent Application Publication Jul. 9, 2015 Sheet 1 of 3 US 2015/O190359 A1 Cumulative release data of iataroprast from i ni is liposames into 40 in PBS pH 7.4 i:38 say F.G. Patent Application Publication Jul. 9, 2015 Sheet 2 of 3 US 2015/O190359 A1 8 8 Patent Application Publication Jul. 9, 2015 Sheet 3 of 3 US 2015/O190359 A1 baseline basise hassissa 2 a as a 4 Essy 2 & 28 Afeek 6 weeks week week. days or weeks F.G. 3 US 2015/O 190359 A1 Jul. 9, 2015 STABLE LIPOSOMAL FORMULATIONS FOR be apparent from the description and from the claims. All OCULAR DRUG DELVERY references cited herein are hereby incorporated by reference in their entirety. BACKGROUND BRIEF DESCRIPTION OF THE DRAWINGS 0001 Intraocular pressure (IOP) in the eye is maintained by a continuous flow of aqueous humor produced by the 0010. The description below refers to the accompanying ciliary body. Excess fluid flows out of the eye through the drawings, of which: trabecular meshwork. If the outflow is blocked, aqueous 0011 FIG. 1 is a plot of cumulative release of latanoprost humor builds up inside the eye leading to increased IOP and from a palmitoyl oleoyl phosphatidylcholine (POPC) lipo ocular hypertension. The ocular hypertension can damage the Some versus time; optic nerve, resulting in an optic neuropathy and irreversibly 0012 FIG. 2a is a plot of the percentage of the starting impaired vision. This condition, known as glaucoma, affects amount of latanoprost remaining in liposomes versus time for more than 60 million people worldwide and is the second egg phosphatidyl choline (PC)-containing liposomes and leading cause of blindness. Increased IOP is the key modifi POPC-containing liposomes; able risk factor for glaucoma. 0013 FIG. 2b is a plot of liposome size versus time of 0002 Conventional treatments for ocular hypertensive storage at 4°C.; and and glaucoma patients include ocular Surgery and topical eye 0014 FIG. 3 is a plot of intraocular pressure versus days drop instillation. These treatment modalities have drawbacks. after a single Subconjunctival injection of latanoprost encap For example, not all patients are candidates for ocular Sur sulated in a POPC-containing liposome gery. Additionally, although topical eye drops are generally considered to be effective, patients long-term compliance DETAILED DESCRIPTION with instillation schedules is a major issue. Ocular hyperten 0015. As mentioned above, a stable liposomal formulation sion and glaucoma cannot be well controlled if patients do not for ocular delivery is provided. The formulation includes a adhere to the proper topical eye drop instillation schedule. liposome containing at least one lipid bilayer that includes a 0003 Topical eye drops contain drugs for controlling IOP phosphatidylcholine. In an embodiment, the liposome is a which typically act by reducing fluid production by the eye, unilamellar vesicle. In a preferred embodiment, the phos increasing fluid outflow, or by both mechanisms. Prostaglan phatidyl choline is palmitoyl oleoyl phosphatidyl choline din analogues, e.g., latanoprost, are potent drugs which can (POPC). reduce IOP by increasing aqueous outflow through the uveo 0016. The formulation also contains a prostaglandin F, Scleral pathway. encapsulated in the liposome. The prostaglandin F, can be 0004 Typically, only 5% of free drug applied to the cor latanoprost, bimatoprost, travoprost, or carboprost. In a pre neal epithelium via eye drops successfully penetrates through ferred embodiment, the prostaglandin F is latanoprost. the cornea. As a result, the amount of drug reaching the 0017. The mole ratio of prostaglandin F, to POPC can be aqueous humor often falls below the therapeutically effective 0.01:1 to 0.5:1. In an embodiment, the mole ratio is 0.01:1 to concentration. This necessitates repeated administration. 0.35:1. In a preferred embodiment, the stable liposomal for Additionally, a Substantial portion of the drug can enter the mulation includes latanoprost and POPC at a mole ratio of circulation via the conjunctival sac, causing undesirable sys 0.01:1 to 0.175:1. Additionally, the liposome can be formu temic side effects. lated to include between 2 and 25 wt % of the prostaglandin F2c. 0005. As an alternative to topical eye drops, subconjunc 0018. The liposome can have a diameter of less than 2 Lum. tival injection of a Sustained release IOP-reducing drug can be In an embodiment, the diameter of the liposome is 100 nm to used to deliver drugs directly to the site of action. Such a 300 nm, e.g., 100 nm, 150 nm, 200 nm, 250 nm, and 300 nm. delivery modality solves the problems of patient non-compli In a preferred embodiment, the diameter is 100 nm. These ance with instillation schedules and inefficient drug transport nano-sized drug-loaded liposomes can release the prostaglan across the cornea. din F, slowly over time. 0006. The need exists for a stable drug formulation for 0019. In an embodiment, the liposomal formulation Subconjunctival injection requiring a minimal frequency of described above can be a pre-constituted, ready-to-inject administration for long-term stable control of IOP aqueous formulation for Sub-conjunctival injection. 0020. Also within the scope of the invention is a method SUMMARY for treating an ocular disorder that relies on administering the liposomal formulation described above. The ocular disorder 0007 To address the need for an improved treatment for can be ocular hypertension or glaucoma. Preferably, the dis intraocular pressure (IOP), a stable liposomal formulation for order is glaucoma. In an embodiment, the liposomal formu ocular delivery is provided. The formulation includes a lipo lation is administered by Subconjunctival injection. Some containing at least one lipid bilayer that includes a 0021 Administering the liposomal formulation described phosphatidylcholine. The formulation also contains a pros above can significantly reduce IOPat one hour post injection. taglandin Fencapsulated in the liposome. Additionally, the More specifically, administering the liposomal formulation liposome has a diameter of less than 2 Jum. results in a reduction in IOP of at least 30% (e.g., 30%, 40%, 0008 Also provided is a method for treating an ocular and 50%) compared to the pretreatment IOP. Advanta disorder by administering the formulation described above. geously, the IOP remains reduced for as long as 4-6 months 0009. The details of one or more embodiments of the following a single injection. invention are set forth in the drawings and description below. 0022. As mentioned above, the injected liposomal formu Other features, objects, and advantages of the invention will lation can slowly release the prostaglandin F, e.g., latano US 2015/O 190359 A1 Jul. 9, 2015 prost, over several months. For example, 50% of the initial latanoprost:POPC mole ratio of 0.175:1 was used to prepare amount of drug in the liposomes can be released within 10 the drug-loaded LUVs. Latanoprost-loaded POPC LUVs days after injection of the formulation into the eye. Prefer were sterile filtered at room temperature using a 0.2 um ably, 65% of the drug is released within 28 days of injection. syringe filter and stored at 4° C. until analyzed. A similar Chronic topical application of anti-glaucoma drugs often method was used to prepare latanoprost-loaded egg PC lipo induces ocular surface disease. The slow-release feature of SOS. the liposomal formulation obviates the need for daily appli cations of these drugs, thereby reducing or eliminating the Example 3 concomitant side effects. 0023 Typically, drugs which are not stable are lyophilized Characterization of Drug Loaded POPC Liposomes or frozen at a temperature of -20°C. or lower to prevent loss 0028 Drug Release studies were performed by dialysing of activity over time. Notably, lyophilizing or freezing sus latanoprost-loaded POPCliposomes prepared as described in tained release formulations of drug-loaded liposomes can EXAMPLE 1 above against PBSata pH of 7.4 and measuring adversely affect the drug release profile, resulting in an unpre by HPLC the amount of latanoprost released. The results are dictable variability in the drug effectiveness. shown in FIG.1. Over a 28 day period, approximately 65% of 0024 Advantageously, the liposomal formulation is stable the latanoprost was released from the latanoprost-loaded for extended periods of time. For example, the formulation POPC liposomes in a time-dependent manner. can be stored at 4°C. for up to 6 months (e.g., 1, 2, 3, 4, 5, and 0029. The physical characteristics of the latanoprost 6 months) without aggregation of the liposomes or loss of loaded POPC liposomes were determined essentially as drug from them. Thus, the liposomal formulation can be described in Venkatraman et al., International Application stored in a vial at 4°C. for extended periods and then can be Publication No. 2012/021107, the content of which is incor directly injected straight from the vial.
Load more

Recommended publications
  • E001466.Full.Pdf
    Editorial BMJ Glob Health: first published as 10.1136/bmjgh-2019-001466 on 11 April 2019. Downloaded from WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? Joshua P Vogel, 1,2 Myfanwy Williams,3 Ioannis Gallos,4 Fernando Althabe,1 Olufemi T Oladapo1 To cite: Vogel JP, THE GLOBAL BURDEN OF POSTPARTUM trials of tranexamic acid for PPH treatment Williams M, Gallos I, et al. HAEMORRHAGE and a heat-stable formulation of carbetocin WHO recommendations on 6–12 uterotonics for postpartum Obstetric haemorrhage, especially post- for PPH prevention. The increasing haemorrhage prevention: partum haemorrhage (PPH), was responsible number of PPH prevention and management what works, and which for more than a quarter of the estimated 303 options makes it challenging for providers one?BMJ Glob Health 000 maternal deaths that occurred globally in and health system stakeholders to choose 2019;4:e001466. doi:10.1136/ 2015.1 PPH—commonly defined as a blood where and how to invest limited resources in bmjgh-2019-001466 loss of 500 mL or more within 24 hours after order to optimise health outcomes. birth—affects about 6% of all women giving Multiple uterotonics have been eval- Handling editor Seye Abimbola birth.1 Uterine atony is the most common uated for PPH prevention over the past Received 4 February 2019 cause of PPH, but it can also be caused by four decades, including oxytocin receptor Revised 10 March 2019 genital tract trauma, retained placental tissue agonists (oxytocin and carbetocin), prosta- Accepted 16 March 2019 or maternal bleeding disorders. The majority glandin analogues (misoprostol, sulprostone, of women who experience PPH have no iden- carboprost), ergot alkaloids (such as ergo- tifiable risk factor, meaning that PPH preven- metrine/methylergometrine) and combina- tion programmes rely on universal use of PPH tions of these (oxytocin plus ergometrine, © Author(s) (or their prophylaxis for all women in the immediate or oxytocin plus misoprostol).
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME PROSTIN 15M 250 microgram (µg)/mL Solution for Injection 2. QUALITATIVE AND QUANTITIATIVE COMPOSITION Each 1 mL contains 250 μg carboprost or 332 μg carboprost (as tromethamine). Excipient(s) with known effect Each 1 mL contains 9.45 mg/mL benzyl alcohol (added as preservative). For the full list of excipients, see section 6.1. 3. PHARMACEUTIAL FORM Solution for Injection. PROSTIN 15M is a clear colourless solution. 4. CLINCAL PARTICUALRS 4.1 Therapeutic indications PROSTIN 15M is indicated for the treatment of postpartum haemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of PROSTIN 15M has resulted in satisfactory control of haemorrhage, although it is unclear whether or not ongoing or delayed effects of previously administered embolic agents have contributed to the outcome. In a high proportion of cases, PROSTIN 15M used in this manner has resulted in the cessation of life threatening bleeding and the avoidance of emergency surgical intervention. 4.2 Dose and method of administration Dose An initial dose of 250 µg (1 mL) is to be given by deep intramuscular injection. In clinical trials, it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome. The need for additional injections and the interval at which these should be given can be determined only by the attending physicians as dictated by the course of clinical events.
    [Show full text]
  • Eicosanoids & Platelet Activating Factor
    Eicosanoids & Platelet Activating Factor Prof. Sanjay Khattri Dept. of Pharmacology & Therapeutics King George’s Medical University, Lucknow 1 Autacoid These are the substances produced by wide variety of cells that act locally at the site of production. (local hormones) 2 Mediators of Inflammation and Immune reaction 1. Vasoactive amines (Histamine and Serotonin) 2.Eicosanoids 3.Platlet Activating Factor 4.Bradykinins 4.Nitric Oxide 5.Neuropeptides 6.Cytokinines 3 EICOSANOIDS PGs, TXs and LTs are all derived from eicosa (referring to 20 C atoms) tri/tetra/ penta enoic acids. Therefore, they can be collectively called eicosanoids. Major source: 5,8,11,14 eicosa tetraenoic acid (arachidonic acid). Other eicosanoids of increasing interest are: lipoxins and resolvins. The term prostanoid encompasses both prostaglandins and thromboxanes. 4 EICOSANOIDS Contd…. In most instances, the initial and rate-limiting step in eicosanoid synthesis is the liberation of intracellular arachidonate, usually in a one-step process catalyzed by the enzyme phospholipase A2 (PLA2). PLA2 generates not only arachidonic acid but also lysoglyceryl - phosphorylcholine (lyso-PAF), the precursor of platelet activating factor (PAF). 5 EICOSANOIDS Contd…. Corticosteroids inhibit the enzyme PLA2 by inducing the production of lipocortins (annexins). The free arachidonic acid is metabolised separately (or sometimes jointly) by several pathways, including the following: Cyclo-oxygenase (COX)- Two main isoforms exist, COX-1 and COX-2 Lipoxygenases- Several subtypes, which
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH HEMABATE® STERILE SOLUTION (carboprost tromethamine injection USP) 250 µg/mL Prostaglandin Pfizer Canada Inc. Date of Revision: 17,300 Trans-Canada Highway February 21, 2014 Kirkland, Quebec H9J 2M5 Control No. 170114 ® Pfizer Enterprises SARL Pfizer Canada Inc, Licensee © Pfizer Canada Inc. 2014 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY OF PRODUCT INFORMATION ..................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................11 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................12 DOSAGE
    [Show full text]
  • Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins
    Article Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins Márton Enesei 1,2,László Takács 2, Enik˝oTormási 3, Adrienn Tóthné Rácz 3, Zita Róka 3, Mihály Kádár 3 and Zsuzsanna Kardos 2,* 1 Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, M˝uegyetemrakpart 3, 1111 Budapest, Hungary; [email protected] 2 CHINOIN, a member of Sanofi Group, PG Development, Tó utca 1-5, 1045 Budapest, Hungary; laszlo.takacs@sanofi.com 3 CHINOIN, a member of Sanofi Group, PG Analytics, Tó utca 1-5, 1045 Budapest, Hungary; robertne.tormasi@sanofi.com (E.T.); adrienn.tothneracz@sanofi.com (A.T.R.); zita.roka@sanofi.com (Z.R.); mihaly.kadar@sanofi.com (M.K.) * Correspondence: zsuzsanna.kardos@sanofi.com Received: 15 June 2020; Accepted: 10 August 2020; Published: 18 August 2020 Abstract: Four enantiomeric forms of natural prostaglandins, ent-PGF α (( )-1), ent-PGE ((+)-2) 2 − 2 ent-PGF α (( )-3), and ent-PGE ((+)-4) have been synthetized in gram scale by Corey synthesis used 1 − 1 in the prostaglandin plants of CHINOIN, Budapest. Chiral HPLC methods have been developed to separate the enantiomeric pairs. Enantiomers of natural prostaglandins can be used as analytical standards to verify the enantiopurity of synthetic prostaglandins, or as biomarkers to study oxidation processes in vivo. Keywords: preparation; ent-PGF2α; ent-PGF1α; ent-PGE2; ent-PGE1; chiral HPLC; enantiomeric separation; mirror images; enantiopurity 1. Introduction Interest in the field of prostaglandins has been steadily growing since the basic work of Bergström Samuelsson, and Vane [1–3]. Their discoveries revealed the structure, the enzyme-controlled biochemical synthesis from arachidonic acid, and the main physiological effects of prostaglandins as well as their related substances.
    [Show full text]
  • Postpartum Haemorrhage
    Guideline Postpartum Haemorrhage Immediate Actions Call for help and escalate as necessary Initiate fundal massage Focus on maternal resuscitation and identifying cause of bleeding Determine if placenta still in situ Tailor pharmacological management to causation and maternal condition (see orange box). Complete a SAS form when using carboprost. Pharmacological regimen (see flow sheet summary) Administer third stage medicines if not already done so. Administer ergometrine 0.25mg both IM and slow IV (contraindicated in hypertension) IF still bleeding: Administer tranexamic acid- 1g IV in 10mL via syringe driver set at 1mL/minute administered over 10 minutes OR as a slow push over 10 minutes. Administer carboprost 250micrograms (1mL) by deep intramuscular injection Administer loperamide 4mg PO to minimise the side-effect of diarrhoea Administer antiemetic ondansetron 4mg IV, if not already given Prophylaxis Once bleeding is controlled, administer misoprostol 600microg buccal and initiate an infusion of oxytocin 40IU in 1L Hartmann’s at a rate of 250mL/hr for 4 hours. Flow chart for management of PPH Carboprost Bakri Balloon Medicines Guide Ongoing postnatal management after a major PPH 1. Purpose This document outlines the guideline details for managing primary postpartum haemorrhage at the Women’s. Where processes differ between campuses, those that refer to the Sandringham campus are differentiated by pink italic text or have the heading Sandringham campus. For guidance on postnatal observations and care after a major PPH, please refer to the procedure ‘Postpartum Haemorrhage - Immediate and On-going Postnatal Care after Major PPH 2. Definitions Primary postpartum haemorrhage (PPH) is traditionally defined as blood loss greater than or equal to 500 mL, within 24 hours of the birth of a baby (1).
    [Show full text]
  • Disruption of Protein-Protein Interactions
    Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2016 Supplementary data Disruption of Protein-Protein Interactions: Hot spot detection, structure-based virtual screening and in vitro testing for anti-cancer drug target – Survivin Sailu Sarvagalla,a Chun Hei Antonio Cheung,b,c Ju-Ya Tsai,b Hsing Pang Hsieh,d and Mohane Selvaraj Coumara,* aCentre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry 605014, India. bDepartment of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan R.O.C. cInstitute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan R.O.C. dInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan, ROC. * Corresponding author: M.S. Coumar; Phone, +91-413-2654950; fax, +91-413-2655211; e-mail, [email protected] S1 Contents A. Figures....................................................................................................................................S3 B. Tables…………………………………………………………………………………….... S6 S2 a Borealin hot spots per-residue energy decomposition 1 0 -1 l -2 o m -3 / l a c -4 k -5 G Δ -6 -7 -8 -9 Residues b INCENP hot spots per-residue energy decomposition 0 l -0.5 o m -1 / l a c -1.5 k -2 G Δ -2.5 -3 Residues Figure S1. Hot spot residue-wise energy contribution for the complex (a) Borealin hot spot residues energy contribution and (b) INCENP protein hot spot residues energy contribution. S3 Figure S2. Mapping of the energetically important residues in CPC interface region. Hot spots, warm hot spots and null spots are represented in red, gold and light green color, respectively.
    [Show full text]
  • PPH 2Nd Edn #23.Vp
    43 Standard Medical Therapy for Postpartum Hemorrhage J. Unterscheider, F. Breathnach and M. Geary INTRODUCTION firm contraction of the organ. If severe haemorrhage has already set in, it is highly recommended that the drug should Failure of the uterus to contract and retract following be given by the intravenous route. For this purpose one-third childbirth has for centuries been recognized as the of the standard size ampoule may be injected or, for those most striking cause of postpartum hemorrhage (PPH) who wish accurate dosage, a special ampoule containing and complicates up to 10% of pregnancies globally. In 0.125 mg is manufactured. An effect may be looked for in less the developing world, PPH is responsible for one than one minute.’ maternal death every 7 minutes1. Another uterotonic agent, oxytocin, the hypothalamic In the 19th century, uterine atony was treated by polypeptide hormone released by the posterior pitu- intrauterine placement of various agents with the aim itary, was discovered in 1909 by Sir Henry Dale8 and of achieving a tamponade effect. ‘A lemon imperfectly synthesized in 1954 by du Vigneaud9. The develop- quartered’ or ‘a large bull’s bladder distended with ment of oxytocin constituted the first synthesis of water’ were employed for this purpose, with apparent a polypeptide hormone and gained du Vigneaud a success. Douching with vinegar or iron perchloride Nobel Prize for his work. was also reported2,3. Historically, the first uterotonic The third group of uterotonics comprises the ever- drugs were ergot alkaloids,
    [Show full text]
  • Inquiry Into Therapeutic Goods Amendment (Repeal of Ministerial
    1 THERAPEUTIC GOODS AMENDMENT (REPEAL OF MINISTERIAL RESPONSIBILITY FOR APPROVAL OF RU486) BILL 2005 INTRODUCTION 1.1 The Therapeutic Goods Amendment (Repeal of Ministerial responsibility for approval of RU486) Bill 2005 (the Bill) is a private Senators' bill that was introduced into the Senate on 8 December 2005 by Senator Nash and also on behalf of Senators Troeth, Allison and Moore. On the same day, 8 December 2005, the Bill was referred on the motion of Senator Troeth to the Committee for inquiry and report by the second sitting day in 2006 (effectively 8 February 2006). 1.2 A majority of the Committee (Senators Adams and Moore dissenting) agreed that a short extension to the reporting date should be sought. Following the receipt of advice relating to Senate business programming, the Committee subsequently agreed (Senator Fielding dissenting) that it would not formally seek an extension from the Senate. THE BILL 1.3 The Bill expresses as its purpose 'to remove the responsibility for approval of RU486 from the Minister and to provide responsibility for approval of RU486 to the Therapeutic Goods Administration'.1 1.4 The Bill achieves this purpose through the amendment of the Therapeutic Goods Act 1989 by repealing subsection 3(1) (definition of restricted goods), section 6AA (importation of restricted goods), section 6AB (exempt goods), section 23AA (ministerial approval of evaluation, registration or listing of exempt goods) and subsection 57(9) (delegation). 1.5 Although the title and stated purpose of the Bill refer only to RU486, the provisions to be repealed by the Bill deal with abortifacient drugs, not specifically RU486.
    [Show full text]
  • Queensland Health List of Approved Medicines
    Queensland Health List of Approved Medicines Drug Form Strength Restriction abacavir * For use in accord with PBS Section 100 indications * oral liquid See above 20 mg/mL See above tablet See above 300 mg See above abacavir + lamivudine * For use in accord with PBS Section 100 indications * tablet See above 600 mg + 300 mg See above abacavir + lamivudine + * For use in accord with PBS Section 100 indications * zidovudine tablet See above 300 mg + 150 mg + 300 mg See above abatacept injection 250 mg * For use in accord with PBS Section 100 indications * abciximab (a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * injection See above 10 mg/5 mL See above abiraterone For use by medical oncologists as per the PBS indications for outpatient and discharge use only tablet See above 250 mg See above 500 mg See above acamprosate Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. enteric tablet See above 333 mg See above acarbose For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents tablet See above 50 mg See above 100 mg See above acetazolamide injection 500 mg tablet 250 mg acetic acid ear drops 3% 15mL solution 2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL Generated on: 30-Aug-2021 Page 1 of 142 Drug Form Strength Restriction acetylcysteine injection For management of paracetamol overdose 2 g/10 mL See above 6 g/30 mL See above aciclovir cream Infectious disease physicians, haematologists and oncologists 5% See above eye ointment For use on the advice of Ophthalmologists only.
    [Show full text]
  • Orange Book Cumulative Supplement 11 November 2019
    CUMULATIVE SUPPLEMENT 11 NOVEMBER 2019 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 39th EDITION Department of Health and Human Services Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy 2019 Prepared By Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 39th EDITION Cumulative Supplement 11 November 2019 CONTENTS PAGE 1.0 INTRODUCTION .......................................................................................................................v 1.1 How to use the Cumulative Supplement ................................................................................v 1.2 Cumulative Supplement Content ......................................................................................... vi 1.3 Applicant Name Changes ................................................................................................. vii 1.4 Levothyroxine Sodium ...................................................................................................... ix 1.5 Availability of the Edition ................................................................................................... xi 1.6 Report of Counts for the Prescription Drug Product List ......................................................... xi 1.7 Cumulative Supplement Legend
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff
    Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 11 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]